top of page
Pipeline Overview
Alera Bio is committed to advancing its technology to develop life-enhancing medicines for people suffering from the devastating neurological effects from chronic conditions.
Our pipeline is focused in three areas:
-
MCT-8 Deficiency
-
Hypothyroidism
-
Hyperthyroidism
Candidate
Description
Target Indication
Lead
Generation
Lead Optimization
IND
Enabling
IND
Phase I
Phase II
Phase III
IND Submission planned
for Q2, 2026
* AB-101 has potential to be able to be in Phase II clinical trials in one year
​
** Additional assets under consideration for licensing
bottom of page